JOURNAL OF MEDICAL CASE

Introduction: Post-traumatic syringomyelia is a progressive degenerative disorder that is a well-recognized sequela of spinal cord injury. There is currently no optimal intervention capable of producing satisfactory long-term clinical results. Case presentation: In this report, we present a 55-year-old Asian man with recurrent syringomyelia after shunt treatment. The syrinx extended from the thoracic cord into the medulla. We used a silicone tube to create a channel connecting the syrinx cavity directly to the fourth ventricle. The patient made a good recovery and follow-up magnetic resonance imaging revealed a considerable diminution in the size of the syrinx. Conclusions: We present a new approach that has the potential to improve the outcome of patients with recurrent post-traumatic syringomyelia, who cannot be treated by conventional methods. Introduction Traumatic spinal cord injury may lead to the development of syringomyelia and the incidence ranges from 0.3% to 3.2% [1]. The pathophysiology may be due to vas-cular, hemorrhagic, or direct mechanical trauma from the original injury, leading to formation of a cavity. Extension of the syrinx may then occur as a result of mechanical forces such as coughing and straining that transmit pressure cephalically or alternatively, from tethering of the cord due to scarring and fibrosis at the injury site [2,3]. Several treatment methods have been attempted, including shunting, laminectomy with aspiration, and syringos-tomy. However, they seldom yield significant functional recovery and recurrence is common. We present a case of spinal trauma complicated by the late development of syringomyelia with recurrence of the syrinx one year after shunt treatment. We introduce a new approach to re-establishing cerebrospinal flow in the subarachnoid space; following intervention, the subject of this case presentation demonstrated improved muscle power in his limbs at two-year follow-up.


Introduction
Allergic bronchopulmonary aspergillosis (ABPA) is a complex hypersensitivity reaction in patients with asthma, which occurs when bronchi are colonized by the fungus Aspergillus, most often Aspergillus fumigatus. The disease is characterized by type I and type III hypersensitivity reactions. The incidence may be as high as 6% of patients with asthma [1]. Repeated episodes of bronchial obstruction, inflammation and mucoid impaction can lead to bronchiectasis, fibrosis and respiratory compromise.
Aspergilloma is a saprophytic growth of fungus, usually A. fumigatus, in the lumen of an existing cavity, which does not invade the tissue. Fungus ball formation has been observed in an old tuberculosis cavity, bronchiectasis, abscess or in a congenital cyst.
We present a case of the coexistence of ABPA and aspergilloma. A patient with ABPA developed a cavitary pulmonary lesion with characteristic radiological appearances of aspergilloma. The management and time sequence of the ABPA and aspergilloma occurrences are discussed.

Case presentation
A 56-year-old Caucasian Slovenian man, who worked as a farmer and was a non-smoker, was treated for bronchopneumonia in the right upper lobe in 1970 and 1974. The infiltrate resolved after antibiotic therapy with penicillin. He also had symptoms of chronic bronchitis, but he did not require therapy.
In 1996, our patient presented with persistent cough, dyspnea and sweats. He had no fever. A general practitioner prescribed him a macrolide antibiotic, but there was no response to this treatment and our patient was referred to a pneumologist. A chest radiograph showed an infiltrate with cavitation in the right lower lobe. Sputum testing for tuberculosis was negative. Tuberculine testing was positive and our patient received tuberculostatic therapy without any improvement over the following four weeks.
On admission to our hospital, he was afebrile and eupnoic. No lymphadenopathy was found. At the auscultation, prolonged expiration and weaker lung sounds over the right basal field were heard. A chest radiograph showed the infiltrates with cavitation in the right lower lobe and in the middle lobe with consolidation of the latter ( Figure 1). Laboratory data showed an elevated erythrocyte sedimentation rate of 66 mm/h and a normal white cell count. Pseudomonas aeruginosa was isolated from the sputum and our patient was treated with ciprofloxacin. Pulmonary function tests showed reduced forced vital capacity (FVC) of 2900 mL (-36%), reduced forced expiratory volume in the first second (FEV 1 ) of 1900 mL (-40%), with the Tiffeneau index of 65%. Arterial blood gas analysis showed only mild hypoxemia (pO 2 9.5 kPa). We also performed fiberbronchoscopy and found a necrotic and purulent mass in the middle lobe bronchus that had practically closed the lumen. Cytological examination of the material obtained with bronchial brushing disclosed numerous eosinophils, Charcot-Leyden crystals and fungal structures morphologically corresponding to Aspergillus spp. (Figure 2). There were no malignant cells. Histological examination of the bronchial biopsy specimen showed chronic inflammatory changes in bronchial mucosa with mononuclear cells and focally granulocytes infiltration. Control fiberbronchoscopy after one week revealed inflammatory infiltration of mucosa in the middle lobe bronchus. Histopathology showed non-specific inflammatory changes of bronchial mucosa. Cutaneous testing for the A. fumigatus antigen was strongly positive. Total serum immunoglobulin E (IgE) concentration was elevated (505 IU/mL), specific IgE against A. fumigatus were strongly elevated (27.9 IU/mL). Serum precipitating antibodies were elevated, specific IgG against A. fumigatus (55 IU/mL) and against A. flavus (51 IU/mL). Metacholine bronchoprovocation testing showed bronchial hyper-responsiveness with the reversibility of obstruction after the bronchodilator. Our patient received methylprednisolone, 32 mg daily. The dose was gradually tapered during the subsequent months.
Pulmonary function tests improved: FVC from 2900 mL to 3100 mL and FEV 1 from 1900 mL to 2200 mL. Total serum IgE concentration fell to 186 IU/ml, specific IgE against A. fumigatus to 6.1 IU/ml, specific IgG precipitating antibodies against A. fumigatus and A. flavus fell to 30 IU/mL and 32 IU/mL, respectively. The chest radiograph disclosed that the infiltrate in the middle lobe resolved, but in the posterior segment of the right lower lobe a cavitary pulmonary lesion with the diameter of 3 cm and with an air crescent was formed. The radiological appearances of this lesion were characteristic of an aspergilloma (Figure 3). Itraconazole 200 mg daily for two months was added to methylprednisolone.
Subsequent controls showed further clinical improvement. The chest radiographs and chest computed   tomography (CT) showed that the aspergilloma became smaller, measuring 2 cm in diameter, and was partially calcified. Fibrotic changes in the right lower and middle lobes were present. Chest CT also showed tram-line shadows of bronchial wall thickening and cylindrical bronchiectasis in the middle lobe ( Figure 4). Specific IgE against A. fumigatus remained elevated (9.4 IU/mL) while specific IgG precipitating antibodies against A. fumigatus and A. flavus normalized (7 IU/mL and 19 IU/mL, respectively). Our patient receives inhalatory steroid and short-acting β 2 -agonist. He is being followed over a five-year period with no signs of recurrence.

Discussion
The coexistence of an aspergilloma and ABPA is a rare finding. Some authors described a development of aspergilloma secondary to ABPA [2][3][4], and others reported ABPA consequent to aspergilloma [5,6]. In 1973 Safirstein described an occurrence of aspergilloma consequent to ABPA [4]. Israel (1980) reported the rapid development of aspergilloma secondary to ABPA with a brief history of preceding asthma [5]. Shah reported, in 1989, two patients with ABPA who later developed aspergillomas and were followed over 30 and 18 months, respectively [6]. In 1979, Ein et al. reported two patients with an ABPA-like syndrome consequent to aspergilloma with subjective and objective improvements after the administration of corticosteroid therapy [7]. Rosenberg (1984) described a patient with such a combination followed over a two-year period [8]. Our patient has been followed over five years and has not shown signs of recurrence which can occur after many years of remission [9]. In 1991, Hefti described a patient with ABPA and aspergilloma in the left upper lobe following a chronic abscessed pneumonia [10]. Shah reported a patient with ABPA and with a middle lobe syndrome [11]. Our patient had some symptoms of obstructive pulmonary disease as early as in 1970, but his dyspnea was not severe and he did not take any therapy. After undergoing bronchopneumonia in 1970 and 1974, only small fibrotic changes were seen on chest radiographs of the right upper lobe of the lung. There was no pathology in the middle or right lower lobes. Thus, at that time, no pulmonary cavities were described where aspergilloma formation could grow. Pulmonary tuberculosis was never proven. Nevertheless, on admission into our hospital in August 1996, a cavity was suggested inside the infiltrate in the right lower lung (Figure 1), which was not seen on the chest radiographs from 1970. It is possible that in 26 years, a cavitary lesion developed where aspergilloma later occurred. The patient had a pulmonary infiltrate in the right lower lobe with endobronchial obstruction of the middle lobe bronchus by an impacted mucus plug. Later, a CT-scan showed cylindrical bronchiectasis of the middle lobe and aspergilloma in the right lower lobe.
This patient was a farmer and therefore his exposure to an environment rich in the Aspergillus spores was high. Vernon et al. found that patients with ABPA had not been more exposed to potentially rich sources of A. fumigatus than atopic control patients. Specific host susceptibility seems to be more important in the pathogenesis of ABPA than environmental factors. However, once the patient is sensitized a minor increase in spore concentration can cause symptomatic disease [12]. The presence of the type I hypersensitivity described in some patients with aspergilloma suggests an immunologic component to this disease which could contribute to a chronic inflammatory response to Aspergillus.
Oral corticosteroids are the therapy of choice in ABPA. Itraconazole may have its role in therapy, especially in cases where oral corticosteroids are contraindicated. In patients requiring high doses of oral steroids itraconazole may allow a reduction in dose, but should not replace the need of corticosteroid treatment [1]. Corticosteroid treatment should result in the reduction of the IgE level (remission or stage II disease). Resolution of pulmonary infiltrates and clinical improvement are generally accompanied by at least a 35% reduction in serum total IgE, which was seen also in our patient. He was treated with oral methylprednisolone for four months. Itraconazole 200 mg daily was added for two months after the resolution of the infiltrate when the aspergilloma in the right lower lobe became visible.